Stock listing

NASDAQ:RPRX Royalty Pharma plc Stock

Home listing (NASDAQ) of Royalty Pharma plc

Follow Royalty Pharma plc into a list and get an email when it puts out news.

Share price · NASDAQ:RPRX

$68.45 USD -0.22 (-0.3%)

Close on Nov 20, 2026

Past year +78.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$67.95 – $68.83 USDNov 20, 2026
Volume
3.53M sharesNov 20, 2026
Market cap
$30.48B USDAt the close on Nov 20, 2026 · price × 445.3M shares outstanding
52-week range
$37.31 – $70.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$198.5M USDMedian day 2.89M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Royalty Pharma plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RPRX · Home$68.45 USD-0.22 (-0.3%)3,531,035$68.17$68.83$67.95$68.67Close on Nov 20, 2026
Frankfurt:RPD€61.01 EUR+0.28 (+0.5%)—€61.01€61.01€61.01€60.73Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RPRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$68.45-0.22-0.3%$68.17$68.83$67.953,531,035
$68.67-0.010.0%$68.73$69.57$68.323,192,451
$68.68+0.155+0.2%$67.92$68.77$67.622,622,511
$68.53-0.785-1.1%$70.00$70.00$68.342,998,938
$69.31+0.34+0.5%$68.77$69.43$68.142,951,218
$68.97-1.04-1.5%$70.34$70.37$68.753,784,342
$70.01+0.56+0.8%$69.04$70.27$68.883,532,759
$69.45+0.68+1.0%$68.26$69.59$67.733,421,218
$68.77+1.47+2.2%$67.50$69.04$66.963,675,372
$67.30-0.27-0.4%$66.52$68.15$66.524,812,984
$67.57+0.010.0%$68.00$69.77$67.514,896,632
$67.56+1.16+1.7%$65.65$67.66$64.843,795,482
$66.40-0.12-0.2%$66.57$67.44$66.123,149,198
$66.52-0.66-1.0%$66.97$67.10$66.432,870,933
$67.18+1.25+1.9%$67.00$67.71$66.404,660,607
$65.93+1.11+1.7%$65.34$66.29$64.932,450,400
$64.82-0.46-0.7%$64.82$65.34$63.492,414,400
$65.28+0.52+0.8%$64.71$65.51$64.452,701,900
$64.76+0.90+1.4%$64.14$65.35$64.064,108,100
$63.86+0.11+0.2%$63.50$63.97$63.014,015,500
$63.75+1.60+2.6%$62.34$63.84$62.342,808,500
$62.15-0.10-0.2%$62.10$62.90$62.002,742,100
$62.25+1.98+3.3%$60.92$62.42$60.782,493,000
$60.27-0.69-1.1%$60.54$61.12$60.042,813,200
$60.96+1.34+2.2%$59.89$61.31$59.725,786,400
$59.62+0.63+1.1%$59.75$60.41$59.503,407,000
$58.99+2.42+4.3%$56.93$59.08$56.782,828,100
$56.57-1.21-2.1%$57.70$57.97$56.423,582,400
$57.78+0.85+1.5%$57.04$57.92$56.852,465,300
$56.93+0.72+1.3%$56.03$57.08$55.722,882,000
$56.21-0.55-1.0%$56.57$56.71$55.132,847,200
$56.76+0.32+0.6%$56.61$57.16$56.413,671,200
$56.44-0.22-0.4%$56.66$57.13$56.042,434,100
$56.66-0.50-0.9%$57.10$57.25$56.013,958,000
$57.16-0.47-0.8%$57.64$57.91$56.962,229,500
$57.63-0.73-1.3%$58.36$58.40$57.223,245,200
$58.36+0.14+0.2%$58.07$58.64$57.703,653,700
$58.22-0.15-0.3%$58.19$58.48$57.512,885,200
$58.37+0.16+0.3%$57.88$58.77$57.631,862,600
$58.21-0.08-0.1%$58.50$58.50$57.681,869,500
$58.29+0.64+1.1%$57.69$58.87$57.662,019,000
$57.65-0.87-1.5%$58.52$59.02$57.632,804,300
$58.52+0.08+0.1%$58.27$59.03$57.862,691,400
$58.44+0.03+0.1%$58.56$59.07$57.823,231,900
$58.41-0.52-0.9%$58.63$58.96$57.977,101,500
$58.93+0.46+0.8%$58.81$59.18$58.462,062,500
$58.470.000.0%$59.00$59.17$58.272,157,600
$58.47-0.58-1.0%$59.00$59.20$57.912,749,600
$59.05+0.44+0.8%$58.66$59.55$57.752,967,200
$58.61-0.14-0.2%$58.95$59.54$58.352,595,900
$58.75-1.84-3.0%$60.45$60.71$58.643,324,500
$60.590.000.0%$60.60$60.80$59.314,344,500
$60.59-3.37-5.3%$59.21$60.86$58.638,631,500
$63.96+0.08+0.1%$63.55$64.38$63.433,401,300
$63.88+0.77+1.2%$63.57$63.94$62.502,761,500
$63.11+0.79+1.3%$62.66$63.29$62.033,142,800
$62.32+0.91+1.5%$61.82$62.58$61.612,629,300
$61.41+0.56+0.9%$60.81$61.68$60.393,894,500
$60.85-1.07-1.7%$61.92$62.01$60.661,701,100
$61.92+0.12+0.2%$61.42$62.35$61.012,093,700
$61.80-0.27-0.4%$62.04$62.28$61.491,478,100
$62.07+0.74+1.2%$61.33$62.46$60.871,705,153
$61.33+0.020.0%$61.19$61.54$60.802,357,873
$61.31+0.73+1.2%$60.53$61.60$60.372,325,100
$60.58-1.15-1.9%$61.33$62.13$60.373,143,000
Ticker
NASDAQ:RPRX
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Royalty Pharma plc news

Royalty Pharma plc on 6ix

News releases
38 in the last 12 months · 198 in all · newest Nov 12, 2026 · oldest 2020
Calls
24 calls with a replay · 24 with a transcript · latest Nov 4, 2026
Decks
68 decks · latest Nov 4, 2026

Where Royalty Pharma plc is listed

ListingExchangeCountryCurrency
NASDAQ:RPRX · Home listing · This pageNASDAQUnited StatesUSD
gettex:RPDgettexGermanyEUR
LS Exchange:A2P62DLS ExchangeGermanyEUR
Tradegate:RPDTradegateGermanyEUR
Lang & Schwarz:A2P62DLang & SchwarzGermanyEUR
Frankfurt:RPDFrankfurtGermanyEUR
BMV:RPRXNBMVMexicoMXN
BX Swiss:RPRXBX SwissSwitzerlandCHF
BIVA:RPRXNBIVAMexicoMXN
BOATS:RPRXBOATSUnited StatesUSD
Dusseldorf:RPDDusseldorfGermanyEUR
Munich:RPDMunichGermanyEUR
Stuttgart:RPDStuttgartGermanyEUR
Hamburg:RPDHamburgGermanyEUR
Hanover:RPDHanoverGermanyEUR
Xetra:RPDXetraGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$38.52B USD
P/E
45.3×
EV/sales
14.7×
EV/EBITDA
25.7×
Price/book
3.1×
Gross margin
87.3%
Operating margin
57.1%
Net margin
25.7%
Debt to equity
0.9×
Beta vs S&P 500
0.22

Forecasts

5 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
72.00 USD · Analysts' mean
EPS, year to Dec 2026
5.39 · 6 analysts
Revenue, year to Dec 2026
3.52B · 5 analysts

Team and board

Officers

OfficerRole
Pablo LegorretaFounder & Chief Executive Officer
Terrance CoyneChief Financial Officer
Arthur McGivernGeneral Counsel & Investments
Nick MontemaranoExecutive Director, Investor Relations
Eric SchneiderChief Technology Officer
Greg RaskinHead of Academic Initiatives
Jim ReddochChief Scientific Officer & Investments
Kenneth SunHead of Asia
Lucas GlassHead of Artificial Intelligence
Marshall UristHead of Research & Investments
Scott RaichilsonChief Accounting Officer

Board

DirectorRole
Bonnie BasslerBoard Member
Carole HoBoard Member
Cathy EngelbertBoard Member
David C. HodgsonVice Chairman
Elizabeth WeathermanBoard Member
Greg NordenBoard Member
Nick MontemaranoExecutive Director, Investor Relations
Pablo LegorretaFounder & Chief Executive Officer
Ted W. LoveBoard Member

Events

Calls

CallWhenStatus
Royalty Pharma (NASDAQ:RPRX) Q3 2026 Earnings CallWed, Nov 04, 2026 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2026 Earnings CallWed, Aug 05, 2026 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q1 2026 Earnings CallWed, May 06, 2026 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2025 Earnings CallWed, Feb 11, 2026 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings CallWed, Nov 05, 2025 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2025 Earnings CallWed, Aug 06, 2025 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q1 2025 Earnings CallThu, May 08, 2025 · 8:30 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2024 Earnings CallTue, Feb 11, 2025 · 8:30 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q3 2024 Earnings CallWed, Nov 06, 2024 · 8:30 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:00 PM ETReplay
All 24 calls
CallWhenStatus
Royalty Pharma (NASDAQ:RPRX) Q1 2024 Earnings CallThu, May 09, 2024 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2023 Earnings CallThu, Feb 15, 2024 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q3 2023 Earnings CallWed, Nov 08, 2023 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2023 Earnings CallTue, Aug 08, 2023 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q1 2023 Earnings CallTue, May 09, 2023 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2022 Earnings CallWed, Feb 15, 2023 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q3 2022 Earnings CallTue, Nov 08, 2022 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q1 2022 Earnings CallThu, May 05, 2022 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2021 Earnings CallTue, Feb 15, 2022 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q2 2021 Earnings CallWed, Aug 11, 2021 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q1 2021 Earnings CallTue, May 11, 2021 · 8:00 AM ETReplay
Royalty Pharma (NASDAQ:RPRX) Q4 2020 Earnings CallWed, Feb 17, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+1.8%
Q2 2026Aug 5, 2026 · Before open+0.5%
Q1 2026May 6, 2026 · Before open+0.6%
Q4 2025Feb 11, 2026 · Before open+0.1%
Q3 2025Nov 5, 2025 · Before open+6.8%
Q2 2025Aug 6, 2025 · Before open−2.1%
Q1 2025May 8, 2025 · Before open+1.1%
Q4 2024Feb 11, 2025 · Before open+1.7%
Q3 2024Nov 6, 2024 · Before open−3.3%
Q2 2024Aug 8, 2024 · Before open−4.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−0.1%
Q4 2023Feb 15, 2024 · Before open+2.5%
Q3 2023Nov 8, 2023 · Before open+0.3%
Q2 2023Aug 8, 2023 · Before open−0.9%
Q1 2023May 9, 2023 · Before open−4.3%
Q4 2022Feb 15, 2023 · Before open−0.8%
Q3 2022Nov 8, 2022 · Before open+0.8%
Q2 2022Aug 4, 2022 · Before open−0.8%
Q1 2022May 5, 2022 · Before open−5.6%
Q4 2021Feb 15, 2022 · Before open+3.1%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings30 slidesNov 4, 2026
Investor Presentation (November 2026)Investor deck91 slidesNovember 2026
Merger or Acquisition (November 2026)Merger or acquisition5 slidesNovember 2026
Q2 2026 Earnings PresentationEarnings33 slidesAug 5, 2026
Investor Presentation (August 2026)Investor deck90 slidesAugust 2026
Investor Presentation (August 2026)Investor deck91 slidesAugust 2026
Merger or Acquisition (August 2026)Merger or acquisition7 slidesAugust 2026
Investor Presentation (July 2026)Investor deck7 slidesJuly 2026
Q1 2026 Earnings PresentationEarnings37 slidesMay 6, 2026
Investor Presentation (May 2026)Investor deck90 slidesMay 2026
Show 50 decks
DeckKindSlidesDate
Merger or Acquisition (March 2026)Merger or acquisition6 slidesMarch 2026
FY2025 Earnings PresentationEarnings41 slidesFeb 11, 2026
Investor Presentation (February 2026)Investor deck86 slidesFebruary 2026
Investor Presentation (February 2026)Investor deck84 slidesFebruary 2026
J.P. Morgan Healthcare Conference 2026Conference35 slidesJan 13, 2026
Investor Presentation (January 2026)Investor deck6 slidesJanuary 2026
Merger or Acquisition (December 2025)Merger or acquisition6 slidesDecember 2025
Investor Presentation (December 2025)Investor deck6 slidesDecember 2025
Q3 2025 Earnings PresentationEarnings32 slidesNov 5, 2025
Investor Presentation (November 2025)Investor deck7 slidesNovember 2025
Investor Day (September 2025)Investor day136 slidesSep 11, 2025
Merger or Acquisition (September 2025)Merger or acquisition7 slidesSeptember 2025
Q2 2025 Earnings PresentationEarnings25 slidesAug 6, 2025
Investor Presentation (August 2025)Investor deck65 slidesAugust 2025
Investor Presentation (August 2025)Investor deck8 slidesAugust 2025
Merger or Acquisition (June 2025)Merger or acquisition8 slidesJune 2025
Q1 2025 Earnings PresentationEarnings25 slidesMay 8, 2025
Investor Presentation (May 2025)Investor deck67 slidesMay 2025
Q4 2024 Earnings PresentationEarnings29 slidesFeb 11, 2025
Investor Presentation (February 2025)Investor deck72 slidesFebruary 2025
Investor Presentation (February 2025)Investor deck67 slidesFebruary 2025
Investor Presentation (February 2025)Investor deck7 slidesFebruary 2025
J.P. Morgan Healthcare Conference 2025Conference26 slidesJan 14, 2025
Merger or Acquisition (January 2025)Merger or acquisition18 slidesJan 10, 2025
Investor Presentation (January 2025)Investor deck67 slidesJanuary 2025
Q3 2024 Earnings PresentationEarnings26 slidesNov 6, 2024
Investor Presentation (November 2024)Investor deck68 slidesNovember 2024
Investor Presentation (November 2024)Investor deck6 slidesNovember 2024
Investor Presentation (November 2024)Investor deck6 slidesNovember 2024
Investor Presentation (September 2024)Investor deck6 slidesSeptember 2024
Q2 2024 Earnings PresentationEarnings31 slidesAug 8, 2024
Investor Presentation (August 2024)Investor deck68 slidesAugust 2024
Q1 2024 Earnings PresentationEarnings31 slidesMay 9, 2024
Investor Presentation (May 2024)Investor deck20 slidesMay 2024
Q4 2023 Earnings PresentationEarnings33 slidesFeb 15, 2024
Investor Presentation (February 2024)Investor deck61 slidesFebruary 2024
Investor Presentation (January 2024)Investor deck60 slidesJanuary 2024
Q3 2023 Earnings PresentationEarnings33 slidesNov 8, 2023
Investor Presentation (November 2023)Investor deck7 slidesNovember 2023
Merger or Acquisition (October 2023)Merger or acquisition27 slidesOct 19, 2023

This page holds 50 of 68 decks. Open Decks

Open Decks

Financings

RaiseDate
Senior unsecured notes
Announced: US$2B · BofA Securities +15
Dealers: BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), J.P. Morgan (co-lead), Morgan Stanley (co-lead), TD Securities (co-lead), Citigroup, DNB Carnegie, SMBC Nikko, SOCIETE GENERALE, US Bancorp, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets LLC, Drexel Hamilton, R. Seelaus & Co., LLC
Use of proceeds: General corporate purposes
Sep 2, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$28.00 a share on Jun 15, 2020.

Price
US$28.00 a share
Shares offered
77,681,670 Class A ordinary shares · 60,000,000 from the company and 17,681,670 from selling shareholders
Offering size
US$2.18 billion
Underwriters' option
Up to 11,652,250 more shares
Underwriters
J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC, Citigroup, UBS Investment Bank, Evercore ISI, Cowen, SunTrust Robinson Humphrey, BBVA, DNB Markets, Scotiabank, TD Securities, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, Cabrera Capital Markets, LLC, R. Seelaus & Co. LLC, Ramirez & Co., Inc., Siebert Williams Shank, Tigress Financial Partners · In the order on the cover
Shares delivered
On or about Jun 18, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 13, 2020
Filed publiclyMay 22, 2020
Amended 3 timesNewest Jun 11, 2020
Shares registered with an exchangeJun 15, 2020
Declared effective by the SECJun 15, 2020
Final prospectus, with the priceJun 17, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jun 17, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.38B2.26B2.35B2.24B2.29B2.12B1.81B1.79B1.60B1.88B
Cost of revenue3.85M732.5M560.7M904.2M452.8M230.8M1.02B136.0M33.3M0
Gross profit2.38B2.26B2.35B2.24B2.29B2.12B1.81B1.79B1.60B1.88B
Research and development452.0M2.00M52.0M177.1M200.1M26.3M83.0M392.6M117.9M91.0M
Selling, general and administrative573.5M236.7M249.7M227.3M182.8M181.7M103.4M61.9M106.4M17.3M
Operating income1.56B1.29B1.49B307.1M1.43B1.60B2.62B1.36B939.7M722.9M
Depreciation and amortization3.85M005.67M23.0M23.1M23.9M33.3M33.3M5.00K
EBITDA1.56B1.29B1.49B312.7M1.45B1.62B2.65B1.40B973.0M722.9M
Interest expense307.7M225.5M187.2M188.0M166.1M157.1M268.6M280.0M247.3M238.9M
Income before tax1.32B1.33B1.70B230.1M1.24B1.70B2.46B1.52B1.34B761.9M
Income tax00000000542.7M196.0M
Net income770.9M859.0M1.13B42.8M619.7M975.0M2.35B1.38B1.21B565.9M
Earnings per share, basic1.791.922.540.101.491.326.633.893.420.93
Earnings per share, diluted1.781.912.530.101.491.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents618.7M929.0M477.0M1.71B1.54B1.01B246.2M1.92B1.38B1.67B
Short-term investments18.8M58.2M18.3M1.30M66.0M70.0M0461.8M
Receivables883.7M27.0M22.4M36.6M68.3M39.2M38.8M198.6M
Inventory11657.1M19.2M
Current assets1.53B1.80B1.27B2.55B2.88B2.70B832.1M2.61B2.95B3.00B
Property, plant and equipment3.00K
Goodwill924.6M0
Total assets19.6B18.2B16.4B16.8B17.5B16.0B12.4B11.4B11.4B10.5B
Accounts payable19.4M13.4M15.2M7.91M5.62M10.8M11.2M4.48M1.88M
Current liabilities636.2M1.25B161.4M1.17B171.3M307.9M333.4M580.2M383.4M297.3M
Long-term debt8.57B6.61B6.14B6.12B7.10B5.82B5.96B6.24B
Total debt8.95B7.61B6.14B7.12B7.10B5.82B6.24B6.52B6.80B5.90B
Total liabilities9.91B7.88B6.30B7.29B7.27B6.12B6.31B6.82B6.90B6.02B
Shareholders' equity9.71B10.3B10.1B9.53B10.2B9.90B6.14B4.55B4.46B4.45B
Shares outstanding559.6M594.0M602.9M564.9M414.8M375.5M354.2M354.2M354.2M607.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations2.49B2.77B2.99B2.14B2.02B2.03B1.67B1.62B1.42B-15.6M
Capital spending00-2.12B-2.04B-523.0K-2.20B-1.72B-269.6M-2.29B0
Free cash flow2.49B2.77B2.99B4.19B2.02B4.23B1.67B1.62B1.42B-15.6M
Cash from investing-1.61B-2.68B-2.07B-1.03B-1.87B-2.76B-2.15B303.4M-1.59B
Cash from financing-1.19B361.1M-2.15B-944.9M385.1M1.49B-1.19B-1.38B-123.3M2.88M
Dividends paid-378.3M-376.5M-358.3M-333.3M-285.2M-397.0M-739.3M-814.4M-735.2M
Share buybacks-1.23B-229.7M-304.8M000-4.27M02.88M
Change in cash-310.3M452.0M-1.23B169.7M532.4M762.5M-1.68B542.6M-292.6M-12.7M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
13F-NTNov 13, 2026Fund holdings reportSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
144 · Notice of proposed saleSep 28, 2026Other filingsSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
144 · Notice of proposed saleSep 22, 2026Other filingsSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 17, 2026Big-stake noticeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
13F-NTAug 14, 2026Fund holdings reportSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 16, 2026Big-stake noticeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Material contractSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
144 · Notice of proposed saleMay 20, 2026Other filingsSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
13F-NTMay 14, 2026Fund holdings reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
8-K · Current reportApr 13, 2026Current reportSEC
ARS · Annual report to shareholdersApr 10, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2026Meeting noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
13F-NTApr 1, 2026Fund holdings reportSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
144 · Notice of proposed saleMar 23, 2026Other filingsSEC
144 · Notice of proposed saleMar 19, 2026Other filingsSEC
144 · Notice of proposed saleMar 18, 2026Other filingsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 20, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
10-K · Annual reportFeb 11, 2026Annual reportSEC
8-K · Current reportFeb 11, 2026ResultsSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
3 · Initial statement of ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 22, 2025Management or board changeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 22, 2025Current reportSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
8-K · Current reportSep 16, 2025Material contractSEC
424B2 · ProspectusSep 3, 2025Offer documentSEC
FWP · Free writing prospectusSep 2, 2025Offer documentSEC
424B2 · ProspectusSep 2, 2025Offer documentSEC
POSASRSep 2, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 13, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
144 · Notice of proposed saleAug 11, 2025Other filingsSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 25, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 25, 2025Insider tradeSEC
8-K · Current reportJul 17, 2025Management or board changeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeMay 23, 2025Big-stake noticeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Acquisition or disposalSEC
S-8 · Registration statement for employee plansMay 16, 2025Offer documentSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
8-K · Current reportMay 12, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 2, 2025Big-stake noticeSEC
4 · Change in ownershipApr 21, 2025Insider tradeSEC

This page holds 200 of 647 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Royalty Pharma plc’s releases · as of Sep 2, 2025

Common shares
445,265,805
Fully diluted
445,265,805

Fully diluted

LineShares
Common shares445,265,805

Share count over time

CountShares
Nov 22, 2026445,265,805

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
New Perspective Fund19.6MUS$1.1BJun 30, 2026
Capital Income Builder7.43MUS$434MJul 31, 2026
Growth Fund of America6.41MUS$358MMay 31, 2026
Growth Portfolio4.91MUS$275MJun 30, 2026
Vanguard Extended Market Index Fund4.47MUS$251MJun 30, 2026
T. Rowe Price Value Fund, Inc.3.12MUS$175MJun 30, 2026
Patient Opportunity Trust2.5MUS$140MJun 30, 2026
VictoryShares Free Cash Flow ETF2.44MUS$137MJun 30, 2026
Fidelity Dividend Growth Fund2.08MUS$121MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.2.06MUS$116MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Extended Market Index Fund1.94MUS$108MMay 31, 2026
Morgan Stanley Discovery Portfolio1.9MUS$107MJun 30, 2026
Transamerica Capital Growth1.86MUS$108MJul 31, 2026
Morgan Stanley Insight Fund1.71MUS$96.1MJun 30, 2026
Invesco Discovery Mid Cap Growth Fund1.71MUS$99.8MJul 31, 2026
iShares Russell Mid-Cap ETF1.7MUS$95.3MJun 30, 2026
Vanguard High Dividend Yield Index Fund1.67MUS$97.3MJul 31, 2026
Growth Fund1.66MUS$93MJun 30, 2026
Fidelity Mid Cap Index Fund1.57MUS$91.6MJul 31, 2026
Fidelity Equity Dividend Income Fund1.53MUS$85.2MMay 31, 2026
Fidelity Low-Priced Stock Fund1.49MUS$87.2MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.36MUS$75.6MMay 31, 2026
Discovery Portfolio1.33MUS$74.5MJun 30, 2026
Fidelity Mid-Cap Stock Fund1.16MUS$67.9MJul 31, 2026
Fidelity Equity-Income Fund1.13MUS$66.2MJul 31, 2026
Select Health Care Portfolio1.12MUS$62.5MMay 31, 2026
Schwab U.S. Mid-Cap ETF1.02MUS$56.8MMay 31, 2026
Capital Group Dividend Growers ETF972KUS$54.2MMay 31, 2026
iShares Russell 1000 Value ETF926KUS$51.9MJun 30, 2026
Vanguard Global Equity Fund925KUS$51.9MJun 30, 2026
iShares U.S. Pharmaceuticals ETF880KUS$49.3MJun 30, 2026
Growth Portfolio779KUS$43.7MJun 30, 2026
Eventide Dividend Opportunities Fund774KUS$43.4MJun 30, 2026
Large-Cap Growth Portfolio755KUS$42.3MJun 30, 2026
Select Pharmaceuticals Portfolio719KUS$40.1MMay 31, 2026
Fidelity Total Market Index Fund711KUS$39.7MMay 31, 2026
VIP Equity-Income Portfolio701KUS$39.3MJun 30, 2026
iShares MSCI USA Momentum Factor ETF654KUS$38.2MJul 31, 2026
iShares Russell Mid-Cap Value ETF636KUS$35.7MJun 30, 2026
Fidelity Advisor Health Care Fund600KUS$35.1MJul 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Large Cap Equity ETF596KUS$33.2MMay 31, 2026
iShares Core Dividend Growth ETF583KUS$34.1MJul 31, 2026
Fidelity Series Total Market Index Fund575KUS$32.1MMay 31, 2026
Fidelity Growth and Income Portfolio571KUS$33.3MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF502KUS$28.1MJun 30, 2026
Franklin Dynatech Fund500KUS$28MJun 30, 2026
Fidelity U.S. Equity Central Fund485KUS$27.2MJun 30, 2026
Value Fund483KUS$27.1MJun 30, 2026
ALPS | OShares U.S. Small-Cap Quality Dividend ETF482KUS$26.9MMay 31, 2026
Fidelity Capital Appreciation Fund471KUS$27.5MJul 31, 2026

This page holds 50 of 482 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Urist Marshall
Officer: EVP, Research & Investments
Sale4,126USD 57.10US$236KOct 5, 2026
Urist Marshall
Officer: EVP, Research & Investments
Sale4,126USD 57.88US$239KSep 28, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale96,073USD 58.51US$5.62MSep 22, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale3,927USD 58.93US$231KSep 22, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale100,000USD 59.97US$6MAug 18, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale9,230USD 58.59US$541KAug 13, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale1,772USD 59.14US$105KAug 13, 2026
Urist Marshall
Officer: EVP, Research & Investments
Sale9,099USD 55.88US$508KJul 1, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale97,446USD 56.50US$5.51MJun 30, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale2,554USD 57.10US$146KJun 30, 2026
All 23 trades
TradeTradeSharesPriceValueDate
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale29,400USD 56.44US$1.66MJun 30, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale600USD 57.09US$34,254Jun 30, 2026
Urist Marshall
Officer: EVP, Research & Investments
Sale9,098USD 55.18US$502KJun 24, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale32,408USD 54.11US$1.75MJun 23, 2026
Hite Christopher
Officer: EVP & Chairman, Partnering
Sale117,592USD 54.47US$6.41MJun 23, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale64,399USD 53.98US$3.48MMay 26, 2026
Urist Marshall
Officer: EVP, Research & Investments
Sale13,684USD 52.75US$722KMay 20, 2026
Norden Gregory
Director
Sale3,045USD 53.00US$161KMay 14, 2026
Urist Marshall
Officer: EVP, Research & Investments
Sale13,684USD 53.06US$726KMay 14, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale32,916USD 49.78US$1.64MApr 28, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale1,875USD 49.78US$93,338Apr 28, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale1,875USD 48.33US$90,619Apr 1, 2026
Coyne Terrance P.
Officer: EVP & CFO
Sale32,916USD 48.33US$1.59MApr 1, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ted W Love
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past)
Director · Since at least Jul 30, 2020
Vlad Coric
Other companies: Veradermics, Incorporated (Board Member · Since at least Feb 3, 2026); Biohaven Ltd. (Chairman & Chief Executive Officer · Since at least Sep 22, 2022); Revance Therapeutics, Inc. (Director · Mar 1, 2023 – Feb 4, 2025 · Past); Akili Inc (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Biohaven Pharmaceutical Holding Co Ltd (Chief Executive Officer, Director · May 3, 2017 – Oct 3, 2022 · Past)
Director · Since at least Apr 7, 2025
Carole Ho
Other companies: Eli Lilly and Company (Executive Vice President and President, Lilly Neuroscience · Since at least Dec 31, 2025); Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Denali Therapeutics Inc. (Chief Medical Officer · Since at least Apr 1, 2019); NGM Biopharmaceuticals Inc (Director · Jun 5, 2020 – Apr 5, 2024 · Past)
Director · Since at least Jul 17, 2025
Elizabeth Weatherman
Other companies: Insulet Corporation (Director · Since at least May 22, 2024); Silk Road Medical Inc (Director · Jun 18, 2024 – Sep 17, 2024 · Past); Vapotherm Inc (Director · Jan 1, 2024 – Sep 20, 2024 · Past); Nevro Corp (Director · Sep 30, 2023 – Apr 3, 2025 · Past)
Director · Since at least Jul 17, 2025
Gregory Norden
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Zoetis Inc. (Director · Since at least Feb 11, 2020); Entasis Therapeutics Holdings Inc (Director · Jun 19, 2019 – Jun 19, 2019 · Past); NanoString Technologies Inc (Director · Jun 18, 2019 – May 6, 2024 · Past)
Director · Since at least Jun 15, 2020
Bonnie Bassler
Other companies: Cidara Therapeutics Inc (Director · Since at least Jan 22, 2021); Regeneron Pharmaceuticals, Inc. (Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University · Since at least Sep 9, 2016); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past)
Board Member · Since at least Jun 15, 2020
Christopher Hite
Other companies: Kailera Therapeutics, Inc. (Independent Board Member · Since at least Apr 16, 2026); Vera Therapeutics, Inc. (EVP and Vice Chairman, Royalty Pharma · Since at least Mar 5, 2026); Acceleron Pharma Inc (Director · Jun 4, 2020 – Nov 19, 2021 · Past)
EVP & Chairman, Partnering · Since at least Jun 15, 2020
Rory Riggs
Other companies: Cibus, Inc. (Director · Since at least May 31, 2023); Kyntra Bio, Inc. (Director · Nov 13, 2014 – May 26, 2021 · Past); Intra-Cellular Therapies Inc (Director · Jan 8, 2014 – Apr 2, 2025 · Past)
Director · Jun 15, 2020 – Feb 20, 2024 · Past
David C. Hodgson
Other companies: Alignment Healthcare, Inc. (Director · Since at least Mar 26, 2021); TriNet Group, Inc. (Director · Since at least Mar 21, 2014)
Vice Chairman · Since at least Jun 23, 2022
Errol B Desouza
Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Cyclerion Therapeutics, Inc. (Director · Nov 30, 2023 – Nov 30, 2023 · Past)
Director · Jun 7, 2024 – May 13, 2025 · Past
All 29 people
PersonSeat
Pablo Legorreta
Other companies: ProKidney Corp. (Chairman of the Board · Since at least Jul 11, 2022); Epizyme Inc (Director · Nov 6, 2019 – Aug 12, 2022 · Past)
Founder & Chief Executive Officer · Since at least Jun 15, 2020
Ted W. Love
Other companies: Gilead Sciences, Inc. (Director · Since at least May 4, 2026); Jazz Pharmaceuticals plc (Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025)
Board Member · Since at least Sep 29, 2025
William E Ford
Other companies: BlackRock, Inc. (Director · Since at least Sep 30, 2020); Ihs Markit Ltd (Director · Dec 15, 2020 – Feb 28, 2022 · Past)
Director · Oct 20, 2020 – Jun 30, 2021 · Past
Catherine M Engelbert
Other companies: McDonald's Corporation (Director · Since at least Dec 31, 2023)
Director · Since at least Jun 7, 2024
Greg Norden
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jun 12, 2026)
Board Member · Since at least Jun 8, 2026
Henry A. Fernandez
Other companies: MSCI Inc. (Chairman and CEO, Director · Since at least Feb 8, 2023)
Director · Since at least Mar 31, 2022
Arthur McGivernGeneral Counsel & Investments · Since at least Jan 1, 2026
Cathy EngelbertBoard Member · Since at least Jun 8, 2026
Eric SchneiderChief Technology Officer · Since at least Nov 4, 2026
Greg RaskinHead of Academic Initiatives · Since at least Aug 3, 2026
James F ReddochEVP & Chief Scientific Officer · May 19, 2022 – Sep 28, 2022 · Past
Jim ReddochChief Scientific Officer & Investments · Since at least Nov 4, 2026
Kenneth SunHead of Asia · Since at least Mar 3, 2026
Lucas GlassHead of Artificial Intelligence · Since at least Mar 23, 2026
Mario Germano GiulianiDirector · Jun 15, 2020 – Jun 23, 2023 · Past
Marshall UristHead of Research & Investments · Since at least Aug 12, 2024
Nick MontemaranoExecutive Director, Investor Relations · Since at least Mar 27, 2026
Scott RaichilsonChief Accounting Officer · Since at least Nov 5, 2026
Terrance CoyneChief Financial Officer · Since at least Aug 12, 2024

Open People

Log in to ask 6ix AI your own questions about Royalty Pharma plc.